Sign In
Buy NBIX
$165.11
+10.27 (+6.63%)
At Close: Jun 03, 2026
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
03:14pm, Tuesday, 02'nd Nov 2021
Investors have grown weary of unpredictable profitability and unexpected expenses.
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2021 Results - Earnings Call Transcript
11:25pm, Monday, 01'st Nov 2021
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2021 Results - Earnings Call Transcript
Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates
06:24pm, Monday, 01'st Nov 2021
Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences: Q3 Earnings Insights
05:11pm, Monday, 01'st Nov 2021
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming
09:00am, Tuesday, 26'th Oct 2021
Our theme of Out Of Favor Health Care Stocks includes biotech and pharma names that are seeing a disconnect between their recent financial performance and recent stock price returns. The theme remains
SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
04:01pm, Monday, 11'th Oct 2021
SAN DIEGO, Oct. 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday,
SAN DIEGO, Oct. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best known for his urban l
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
09:23am, Friday, 10'th Sep 2021
SAN DIEGO, Sept. 10, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) a
Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound
10:00am, Wednesday, 11'th Aug 2021
Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phas
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2021 Results - Earnings Call Transcript
09:15pm, Tuesday, 03'rd Aug 2021
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2021 Results - Earnings Call Transcript
Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates
07:04pm, Tuesday, 03'rd Aug 2021
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
04:01pm, Monday, 19'th Jul 2021
SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesda
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference
04:01pm, Thursday, 08'th Jul 2021
SAN DIEGO, July 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a neuropsychol
